The patient Medication Guide provides the most important information about taking LETAIRIS. Any questions or concerns should be discussed with a healthcare professional.
LETAIRIS can cause serious birth defects if taken during pregnancy. Women must not be pregnant when they start taking LETAIRIS or become pregnant during treatment. Women who are able to get pregnant must have a negative pregnancy test before beginning treatment with LETAIRIS and each month during treatment. Your doctor will decide when to do the test, depending on your menstrual cycle.
Women who are able to get pregnant must use two acceptable forms of birth control, during LETAIRIS treatment and for one month after stopping LETAIRIS. If you have had a tubal sterilization or have an IUD, these methods can be used alone and no other form of birth control is needed. Talk with your doctor or gynecologist (a doctor who specializes in female reproduction) to find out about how to prevent pregnancy. Do not have unprotected sex. Talk to your doctor or pharmacist right away if you have unprotected sex or if you think your birth control has failed. Tell your doctor right away if you miss a menstrual period or think you may be pregnant.
LETAIRIS is available only through a restricted program called the LETAIRIS Education and Access Program (LEAP). To receive LETAIRIS, you must talk to your doctor, understand the benefits and risks of LETAIRIS, and agree to all of the instructions in the LEAP program.
LETAIRIS is a prescription medicine to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of your lungs.
LETAIRIS can improve your ability to exercise and it can help slow down the worsening of your physical condition and symptoms.
Do not take LETAIRIS if:
Tell your doctor about all your medical conditions and all the medicines you take including prescription and nonprescription medicines. LETAIRIS and other medicines may affect each other causing side effects. Do not start any new medicines until you check with your doctor.
Especially tell your doctor if you take the medicine cyclosporine (Gengraf®, Neoral®, Sandimmune®). Your doctor may need to change your dose of LETAIRIS. You should not take more than 5 mg of LETAIRIS each day if you also take cyclosporine.
LETAIRIS has not been studied in children.
LETAIRIS will be mailed to you by a Certified Specialty Pharmacy. Your doctor will give you complete details.
Do not get pregnant while taking LETAIRIS. (See the serious birth defects section of "What is the most important information I should know about LETAIRIS?") If you miss a menstrual period, or think you might be pregnant, call your doctor right away.
Breastfeeding is not recommended while taking LETAIRIS. It is not known if LETAIRIS can pass through your milk and harm your baby.
Serious side effects of LETAIRIS include:
The most common side effects of LETAIRIS are:
Some medicines that are like LETAIRIS can cause liver problems. Tell your doctor if you get any of these symptoms of a liver problem while taking LETAIRIS:
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of LETAIRIS. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Store LETAIRIS at 59 °F to 86 °F (15 °C to 30 °C), in the package it comes in.
Keep LETAIRIS and all medicines out of the reach of children.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use LETAIRIS for a condition for which it was not prescribed. Do not give LETAIRIS to other people, even if they have the same symptoms that you have. It may harm them.
This Medication Guide summarizes the most important information about LETAIRIS. If you would like more information, ask your doctor. You can ask your doctor or pharmacist for information about LETAIRIS that is written for healthcare professionals.
For more information, call 1-866-664-LEAP (5327) or visit www.letairis.com or www.gilead.com.
Active ingredient: ambrisentan
Inactive Ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose. The tablets are film-coated with a coating material containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
Revised March 2011
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Gilead Sciences, Inc., Foster City, CA 94404
LETAIRIS is a registered trademark of Gilead Sciences, Inc. Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. Other brands noted herein are the property of their respective owners.
© 2011 Gilead Sciences, Inc.
GS22-081-007
If you have questions or concerns regarding your treatment options, call 1-866-664-LEAP (5327) or visit www.gilead.com for more information.